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Abstract
Introduction
TP53 mutation carrier (Li-Fraumeni Syndrome, LFS) cohort studies often suffer from lack of
extensive pedigree exploration.
Methods
We performed a nation-wide exploration of TP53 mutation carrier families identified through
all clinical genetics departments in Denmark. Pedigrees were expanded and verified using
unique national person identification, cancer, cause of death, pathology, and church
registries.
Results
We identified 30 confirmed, six obligate and 14 assumed carriers in 15 families harboring 14
different mutations, including five novel and three de novo germline mutations. All but two
(96%) developed cancer by age 54 years [mean debut age; 29.1 y., median 33.0 y., n = 26
(17F, 9M), range 1–54 y]]. Cancer was the primary cause of all deaths [average age at
death; 34.5 years]. Two tumors were identified through registry data alone. Two indepen-
dent families harbored novel c.80delC mutations shown to be related through an ancestor
born in 1907. This exhaustive national collection yielded markedly fewer TP53 mutation car-
riers than the 300–1,100 expected based on estimated background population frequencies.
Conclusion
Germline TP53 mutations in Denmark are likely to be drastically underdiagnosed despite
their severe phenotype. Following recent advances in surveillance options of LFS patients,
lack of pre-symptomatic testing may lead to the mismanagement of some individuals.
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Introduction
Li-Fraumeni Syndrome (LFS; Online Mendelian Inheritance in Man entry [OMIM] 151623) is
an autosomal dominant cancer predisposition syndrome caused by germline mutations in
TP53 [1]. The known tumor spectrum of LFS comprises nearly all tissues, hazard ratios being
especially increased for osteosarcomas, adrenocortical carcinomas (ACC), central nervous sys-
tem (CNS) tumors, and soft tissue sarcomas, as well as breast cancer in younger women [2]. In
four of the rare malignancies: childhood ACC, anaplastic rhabdomyosarcoma, choroid plexus
carcinoma, and low hypodiploid acute lymphoblastic leukemia, TP53 mutation carriers
account for 40–80% of all patients [3–5].
LFS is suspected based on phenotype criteria and confirmed by identifying a pathogenic
germline variant in TP53, however, germline mutations may be missing in some families with
characteristic LFS patterns of cancer, and conversely as many as 20% of patients have de novo
mutations and are thus without a LFS pattern family history of cancer [6].
The lifetime risk of cancer has been estimated at around 70% for men and approaching
100% for women, with approximately one third developing cancer before age 18 years [2,7].
LFS is believed to be markedly underdiagnosed. A recent germline genomic study of>1,000
childhood cancer patients identified 50 TP53 mutation carriers, most of whom lacked a family
cancer history supporting LFS, however the study was markedly enriched with patients with
tumors within the LFS spectrum [5].
The International Agency for Research on Cancer (IARC) curates the most comprehensive
database of germline TP53 mutations with 1,827 confirmed carriers as of April 2016 (Version
R18, http://p53.iarc.fr/). This relatively limited number of entries in the IARC database con-
trasts the anticipated frequency of TP53 mutation carriers from 1 in 5,000 to 20,000 individuals
in the general population [8,9]. This most likely stems from an underreporting of TP53 germ-
line mutations from the diagnostic genetic laboratories, but also hints at a possible under-diag-
nosis of LFS globally.
Pathogenic mutations of the TP53 gene can result in either loss-of-function or a gain-of-
function/dominant negative effect. Dominant negative mutations in the DNA-binding
domain blocks the function of the wild-type allele and are thus generally associated with cancer
debut at an earlier age than loss-of-function mutations [2].
Sequencing of TP53 is inconsistently offered to patients or families harboring LFS pheno-
types. However, this tendency is shifting due to decreasing costs of sequencing, potential bene-
fits of tumor surveillance, need for individualized chemo- and radiotherapy in patients with
LFS, and emerging reproductive options including preimplantation genetic diagnosis [10–13].
Methods
Information on TP53 mutation carriers was obtained from all departments of clinical genetics
in Denmark. Only families with clinically confirmed TP53 mutations were included. In addi-
tion, one Danish family (family #11) was identified from the IARC database [14]. Access to
electronic medical records (EMRs) was obtained by individual contact to the clinical genetics
departments. EMRs included pedigrees taken and expanded at the time of LFS diagnosis, his-
tological pathology reports of tested individuals with a cancer diagnosis, and laboratory reports
of TP53 sequencing. All pedigrees were expanded further through the unique identification
numbers in The Danish Personal Identification Number Registry (CPR, every Danish citizen
alive in 1968 or later) and/or Church registries. CPR-numbers are linked to first-degree rela-
tives which allow for the extension of pedigrees, which was done by at least one generation
above the oldest known affected individual wherever possible. Subsequently CPR numbers
were linked to registry data from 1) the Danish Cancer registry (all cancer diagnoses from
A nationwide clinical characterization of germline TP53 mutations
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1943 to 2014), 2) the Danish Cause of Death Registry (deceased after 1970 and before 2014),
and 3) the Danish Pathology Registry (tissues described 1970 or later). Information on recep-
tor status in breast cancers was included when available. CPR provided death status for sub-
jects after 2014. Through church registries and censuses, two families not previously known to
be related (#5 and #13) were backtracked to a shared female relative born in 1907.
Starting in June 2012, a gene panel has been used in the oncological management of breast
cancer (BC) patients at one Danish hospital to screen women for mutations in genes associated
with increased risk of breast cancer, including BRCA1, BRCA2, CDH1, PTEN, RAD51C and
TP53. The criteria for panel testing were<40 years at BC diagnosis, triple negative BC, bilat-
eral or multifocal BC, or BC and family history of breast/ovarian cancer. One individual (sub-
ject II.2 in family #7) was 41 years at diagnosis and had no first- or second-degree family
members with cancer, however, more distant relatives had cases of middle-age breast cancer,
and it was decided to test the youngest individual in the family. LFS families identified through
BC panel testing were compared to families diagnosed through other investigations, to exam-
ine pheno- and genotype differences.
Putative dominant negativity was defined as a pathogenic missense mutation inside the
DNA-binding domain (DBD) of the TP53 gene, and cancer debut age in individuals carrying
TP53 missense mutations inside the DBD vs. individuals carrying TP53 mutations outside or
non-missense TP53 mutations inside the DBD, was tested (S1 Fig).
TP53 analysis was performed by Sanger sequencing until 2012 and from 2012 and onwards
by next-generation sequencing (NGS) analysis as recently described [15]. Briefly, the NGS
sequence capture library (Roche NimbleGen) was designed to capture all exons from the TP53
gene (NM_000546) as well as five other genes (BRCA1, BRCA2, CDH1, PTEN, RAD51C).
Sequencing was performed on a MiSeq (llumina) to an average coverage of at least 100x.
Sequencing data were analyzed using Sequence Pilot software (JSI medical systems). Variants
were called if the allele frequency was above 25%, except for formalin-fixed paraffin-embedded
(FFPE) tissue where specific mutations were examined in all sequence reads. Copy number
variations were detected by multiplex ligation-dependent probe amplification (MRC-Holland)
analysis or by analysis of NGS data. All nucleotide variants were verified by Sanger sequencing
on an ABI 3730 DNA Analyzer using DNA purified from a new blood sample.
Untested LFS relatives were classified as either 1) obligate carriers or 2) probable carriers,
defined as untested relatives of a carrier with either pathogenomic cancers (e.g. ACC) or onset of
a cancer on the LFS spectrum before age 46 or multiple primaries consistent with LFS at any age.
The project is approved by the Danish Health Authority and the need for individual con-
sent was waived. Based on the waiver the ethical committees in Denmark determined that the
study was not subject to their approval (jr.n. 15012065).
Results
The clinical genetics departments provided a total of 15 LFS families harboring 14 different
mutations; five novel germline mutations not previously described in the IARC database, two
mutations seen in single families (one and two confirmed cases each), three mutations seen in
two families, and four frequently reported mutations (Fig 1 and Table 1) [16]. One of the novel
mutations (c.80delC) was identified in two independently diagnosed families (#5 and #13, see
Methods) that were subsequently shown to be distantly related. Time since genetic diagnosis
in the families ranged from 2002 to 2016, with all but four families being diagnosed during or
after 2012.
The 15 families contained 30 confirmed, six obligate, and 14 probable carriers, collectively
diagnosed with 50 malignant tumors (excluding four non-melanoma skin cancers). 33 (66%)
A nationwide clinical characterization of germline TP53 mutations
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cancers were observed among 26 confirmed or obligate TP53 carriers and another 17 (34%)
observed in 14 probable carriers (Table 2 and S1 Table).
Age at diagnosis of first cancer among the 26 affected carriers, including obligate carriers,
was a mean of 29.1 years and median of 33.0 years, n = 26 (17F, 9M), [range 1–54 years] and
all fatalities occurred with cancer being the primary cause of death (average; 34.5 years [7–60],
n = 16). We found no age difference in cancer debut between carriers with and without
Fig 1. (A) Pedigrees of three Danish families harboring germline TP53mutations. (B) NM_000546 isoform of the
TP53 gene protein product showing the mutations found in this study (upper track) and all published mutations from
the IARC database (lower track). In the upper track, 5 novel germline mutations described in this study are expanded.
In the lower track, mutations from 9 loci in the IARC database are expanded, corresponding to the 9 non-novel
mutation sites described in this study. 14 IARC mutations were left out as they were either complex (13) or not
classified (1). Variant colors: blue, missense, orange, nonsense, purple, splice region, red, frameshift, green, silent, grey,
protein deletion.
https://doi.org/10.1371/journal.pone.0190050.g001
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putative dominant-negative TP53 mutations (25.9 versus 28.7 years, p = 0.65) (S1 Fig). Antici-
pation in LFS families has been previously demonstrated, however, we were unable to show
any significant anticipation, likely due to the size of the cohort [17] (S2 Table).
A recent study established a link between development of choriocarcinoma in non-carrier
mothers pregnant with a TP53 mutation carrier fetus [13]. Among the TP53 mutation-negative
females in this study who 1) had a TP53 mutation-positive partner and 2) gave birth to off-
spring with either confirmed or unknown TP53 mutation status, no cases of choriocarcinoma
were found (N = 10).
Among gene panel screening of 982 female BC (breast cancer) patients [average age; 48.2
years], two were found to harbor a TP53 mutation, indicating a frequency of germline TP53
mutations in 0.2% of women with BC fulfilling the criteria for genetic screening. In total eight
families were identified solely due to their family BC history (families #4, #5, #6, #7, #8, #10,
#13, and #15). These families had a significantly older average age of first cancer when com-
pared to the seven LFS families identified through other means (35.8 vs. 21.7 years, p = 0.01).
Five novel germline TP53 pathogenic variants
Family #1 harbored a c.614A>G, p.(Tyr205Cys), missense mutation in exon 6. This locus is a
hotspot for somatic mutations in the TP53 gene with 86 reported somatic mutations, including
in five astrocytomas. Transcriptional assays of the somatic variant have classified it as non-
functional [18]. The germline variant was found in all three daughters of the mother (subject
II.4). The mother developed invasive ductal carcinoma (IDC) of the breast at age 35. Two of
her daughters developed liposarcoma and astrocytoma at ages 7 and 18 years, respectively.
Family #3 harbored a germline splice donor site mutation. The c.672+2T>G, p.?, intron 6,
splice mutation was found in subject III.5, who developed a leiomyosarcoma and pancreatic
Table 1. IARC database characteristics of germline TP53 mutations observed in both IARC and in this study (families with more than 10 confirmed carriers in the
IARC database are in bold).
Fam
#
Mutation # of
families
# of
carriers
Perc. with
cancer
Mean age at
first cancer
Perc. with >1
cancer
Perc. with
cancer <18y
Perc. by cancer site: breast/
brain/ST/bone/other
2 c.524G>A, p.(Arg175His),
exon 5, missense
33 54 88.9% (48) 21.9y 38.9% (21) 29.6% (16) 28%/17%/16%/9%/29% (75)
4 c.993G>A, p.?, exon 9, splice 1 2 100% (2) 21.5y 0.0% (0) 50.0% (1) 50%/0%/0%/0%/50% (2)
6 c.818G>A, p.(Arg273His),
exon 8, missense
31 42 90.5% (38) 20.5y 40.5% (17) 35.7% (15) 22%/10%/24%/16%/29% (63)
8 c.584T>C, p.(Ile195Thr), exon
6, missense
2 2 100% (2) 22.5y 50% (1) 0.0% (0) 33%/33%/0%/0%/33% (3)
9 c.742C>T, p.(Arg248Trp),
exon 7, missense
27 58 93.1% (54) 19.8y 39.7% (23) 39.7% (23) 28%/25%/7%/7%/33% (88)
10 c.799C>T, p.(Arg267Trp),
exon 8, missense
2 2 50.0% (1) N/A 0.0% (0) 0.0% (0) 100%/0%/0%/0%/0% (1)
11 c.919+1G>A, p.?, intron 8,
splice ᵻ
4 7 71.4% (5) 14.8y 28.6% (2) 28.6% (2) 28%/14%/28%/14%/14% (7)
14 c.451C>T, p.(Pro151Ser), exon
5, missense
2 2 100% (2) 12.5y 50% (1) 50% (1) 25%/0%/0%/0%/75% (4)
15 c.845G>A, p.(Arg282Gln),
exon 8, missense
1 1 100% (1) 1y 100% (1) 100% (1) 0%/0%/0%/0%/100% (2)
Table was constructed using data from The International Agency for Research on Cancer (IARC) TP53 mutation registry version R18, April 2016. Families #1, #3, #5,
#7, #12 and #13 are not listed as they carried germline TP53 mutations not described in the IARC database. Mutations are described according to NM_000546.5. N is
given in parenthesis for each percentage.
ᵻ This mutation includes data also presented in this study. Perc., percentage, #, number,<18y, under 18 years of age, ST, soft tissue.
https://doi.org/10.1371/journal.pone.0190050.t001
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Table 2. Clinical and mutational data of families with 36 confirmed or obligate germline TP53 mutations carriers.
Fam
#
Pt # Sex Tumor(s)ᵻ Age at
Dx
2nd Age at
death
Criteria Mutation Domain IARC Fq
ᵻ ᵻ
Note
1 III.2 F Anaplastic astrocytoma (H) 18 - - LFS c.614A>G, p.(Tyr205Cys),
exon 6, missense
DNA-
binding
novel
III.4 F Liposarcoma (H) 7 - -
II.4 F IDC, ER+, HER- (H) 35 - 37
2 V.1 M Sarcoma of thorax (R) 8 - 9 LFS c.524G>A, p.(Arg175His),
exon 5, missense
DNA-
binding
54(33)
IV.1 M Adrenocortical carc. (H) 28 - 31
3 III.5 M Leiomyosarcoma (H) Pancreatic
(H)
38 8 47 LFS c.672+2T>G, p.?, intron 6,
splice
- novel
III.1 F IDC, ER-, HER+ (H) 21 - -
II.2 M Melanoma (H)
Leiomyosarcoma (H)
46 12 60
4 III.2 F IDC, ER+ (H)
CRC acendens (H)
35 6 43 Chompret c.993G>A, p.?, exon 9, splice Oligomeriz. 2(1)
5 IV.2 F IDC, ER+, HER+ (H) 23 - - LFS c.80del, p.(Pro27Leufs17),
exon 4, frameshift
several novel
III.2 F IDC, ER- (H)
Ovarian seropap. carc. (D)
35 16 54
II.2 M Adenocarc. oesoph. (H) 54 - 54
6 III.2 F IDC, ER+, HER+ (H) 53 - - none c.818G>A, p.(Arg273His),
exon 8, missense
DNA-
binding
42(31) (putativemosaic)
7 II.2 F IDC, ER+, HER+ (H) 41 - - none c.528C>A, p.(Cys176),
exon 5, nonsense
several novel (de novo)
8 III.2 F IDC, ER+ (H) 38 - 56 LFS c.584T>C, p.(Ile195Thr),
exon 6, missense
DNA-
binding
2(2)
9 II.1 F Choroid plexus carc. (H) 12 - - Chompret c.742C>T, p.(Arg248Trp),
exon 7, missense
DNA-
binding
58(27) (de novo)
10 III.10 F IDC. ER+, HER+ (H) 37 - 43 Chompret c.799C>T, p.(Arg267Trp),
exon 8, missense
DNA-
binding
2(2)
III.4 F Oligodendroglioma II (H) 31 - 36
11 III.2 M Leydig cell tumor (H)
PNET (H)
1 5 7 Chompret c.919+1G>A, p.?, intron 8,
splice
- 7(4) [15]
II.2 M Leiomyosarcoma (R) 45 - -
12 III.2 F Anaplastic RMS (H)
Glioblastoma (H)
2 11 - LFS c.994_1139del, p.(Ile332),
exon 9, nonsense
several novel
II.2 F Glioblastoma (H) 28 - 29
13 III.4 F IDC, ER+ (R) 28 - 33 Eeles Shown to have the same mutation as Fam #5
II.4 M Ductus choled. carc. (R) 44 - 44
14 II.2 M Fibrous histiocytoma (H)
Dermafibrosarcoma (H)
3 2 17 None c.451C>T, p.(Pro151Ser),
exon 5, missense
DNA-
binding
2(2)
15 III.3 F CRC, sigmoid (H) 45 - - Eeles c.845G>A, p.(Arg282Gln),
exon 8, missense
DNA-
binding
1(1)
Mutations are described according to NM_000546.5. Nine unaffected TP53 mutation carriers (one male) from 5 different families and one obligate carrier with
unknown cause of death and cancer status are not included in the table. The nine unaffected carriers had an average age at time of study of 41,6 years [range 17-81y].
ᵻ strongest evidence for disease given in parentheses with H, histology, R, registry, D, death certificate,
ᵻ ᵻ Fq, frequency; number of times mutation is seen in IARC TP53-database with number of confirmed carriers (number of families in parentheses) novel indicates
novelty on a germline level. Cancer was the primary cause of all deaths. Italics indicate obligate carrier. 2nd, years until second primary cancer following cancer debut,
, nonsense codon, del, deletion, PNET, primitive neuro-ectodermal tumor, CRC, colorectal cancer, RMS, rhabdomyosarcoma, IDC, invasive ductal carcinoma, ER,
estrogen receptor positive, HER, herceptin receptor positive, +/-, positive/negative (where receptor status is not given it is unknown), NOS, not otherwise specified,
carc., carcinoma, adenocarc., adenocarcinoma, oesoph., oesophageal, seropap., seropapillary, choled., choledochus.
https://doi.org/10.1371/journal.pone.0190050.t002
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cancer at age 38 and 46 years, respectively. His father developed both melanoma and leiomyo-
sarcoma at age 46 and 58 respectively, and his sister had a melanoma at age 46 (not included in
the Table 2 and S1 Table as she did not fulfill the criteria for being a probable carrier), and a
daughter with IDC at age 21.
Family #7 harbored a c.528C>A, p.(Cys176), nonsense mutation in exon 5 leading to a
stop-gain at codon 176. The mutation was found in a woman (II.2) with ER- and HER-positive
IDC of the breast at age 41. Her parents (I.1 and I.2) were both tested negative for the muta-
tion, suggesting a de novo mutation although germline mosaicism cannot be excluded.
Family #12 harbored a c.994_1139del, p.(Ile332), nonsense mutation in exon 9, detected in
a girl (III.2) who developed anaplastic rhabdomyosarcoma at age 2 and a second primary
(astrocytoma) at age 13. Her mother (II.2) also carried the deletion and was diagnosed with
glioblastoma at age 28 years. The mutation was likely inherited from her mother (I.2), diag-
nosed with bilateral breast cancer at 23.
Family #5 and #13 both harbored a c.80del, p.(Pro27Leufs17), frameshift mutation in exon
4 leading to a premature stop at codon 43. The mutation was first found in a woman (IV.2)
with ER- and HER-positive IDC of the breast at age 23, who had a brother (IV.5) diagnosed
with rhabdomyosarcoma at age one year. Their mother (III.2) had IDC of the breast and ovar-
ian papillary serous cystadenocarcinoma at age 35 and 51 respectively. Subject III.2 had a sister
(III.3) who developed ovarian papillary serous cystadenocarcinoma, and her daughter (IV.2)
was diagnosed with IDC of the breast at age 22 years. The dual observation of this novel muta-
tion initiated the linkage of these families to a common female ancestor, established through
Danish church registries. She was born in 1907 and likely died sometime before 1970, meaning
she reached a maximum age of 63. Her cause of death and cancer status is unknown.
The five variants described above have, to our knowledge not been reported before at the
germline level, but four of them (c.614A>G, c.80delC, c.528C>A, c.672+2T>G) have been
identified as somatic mutations in various cancers.
Of the seven non-Danish Scandinavian mutations registered in the IARC LFS database
only the c.993G>A mutation, resulting in a silent p.Q331Q amino acid change, overlapped
with the mutations reported in this study. A previous report predicted this mutation to cause a
loss of the splice donor signal and likely skipping of exon 9. Expression arrays indicated that
the mutation results in an unstable mRNA transcript degraded by nonsense-mediated decay.
[19] The mutation’s pathogenicity is further evidenced by family #4 in this study, that fulfills
the Chompret criteria. No relationship between the families could be established.
By using registries to validate or discover cancers, 10 unreported tumors were discovered.
These included eight non-melanoma skin cancers/cervix dysplasia found among both TP53
mutation carriers and non-carriers, and excluded from our data due to their high rate of spo-
radic occurrence in the general population. The remaining two occurred in TP53 mutation
carriers and included a sarcoma of the thorax in an eight-year-old boy (V.1, family #2), and a
leiomyosarcoma in a 45-year-old male (II.2, family #11).
Discussion
This study found 50 confirmed, obligate, or probable TP53 mutation carriers, yet the reported
TP53 mutation general population incidences of 1 in 5,000–20,000 should yield between 285
and 1,141 carriers in Denmark (population: 5,7 million). This could indicate that TP53 muta-
tions are underdiagnosed in Denmark, partly reflecting that TP53 mutations are frequently
found in cancer patients without significant family histories. If accurate this could be due to a
higher frequency of de novo mutations and mosaicism, a lower penetrance compared to previ-
ous reports or, as shown for BRCA mutation carriers in previous studies, limited family
A nationwide clinical characterization of germline TP53 mutations
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structure defined as fewer than 2 first- or second-degree relatives surviving beyond 45 years in
either lineage [5,20,21]. However, the relevance of the limited family structure differs for TP53
mutation carriers as compared to BRCA mutation carriers, because TP53 mutations have a
markedly higher penetrance in males and carriers have a markedly lower age at first cancer
diagnosis, typically debuting before 45 years of age. Furthermore, the testing of TP53 mutation
status has historically been limited in the clinically, even in cases where suspicion of LFS was
raised. Testing was deferred due to limited possibilities of surveillance, and at the time no evi-
dence of reduced mortality following genetic testing existed.
For TP53 mutation carriers, the question of tumor surveillance is highly relevant. Among
the 11 TP53 mutation carriers in this study who, at the time of genetic investigation, hadn’t
had cancer, two subsequently developed cancer, and could potentially have benefited from a
cancer surveillance program. Recent results from use of the extensive “Toronto protocol”,
which includes yearly whole-body and cerebral MRIs, indicated a survival benefit in TP53
mutation carriers with 5-year overall survival rates of 89% in the surveillance group versus
60% in the non-surveillance group. However, the study was non-randomized and the two
groups had remarkably and inexplicably different tumor incidences, (49% and 88% in surveil-
lance versus non-surveillance groups, respectively). This is counterintuitive as one would
expect similar or higher incidence in the surveillance group [11], however several of the lesions
identified in the surveillance group were in fact pre-cancerous or low-grade tumors, with early
detection leading to curative surgical treatment. Conclusively, the benefit of comprehensive
surveillance programs awaits further data. One study has shown that, a targeted surveillance
approach for ACC in TP53 mutation carriers before age 15, decreases at-diagnosis tumor size
with a trend towards lower stage and increased surgical cure in the surveillance group [22].
Numerous countries have adopted versions of comprehensive surveillance programs and the
American Association for Cancer Research has recently issued a recommendation for screen-
ing of individuals with LFS [23]. Furthermore, it is widely believed that female TP53 mutation
carriers could benefit from breast cancer surveillance similarly to BRCA1/2mutation carriers,
yet using non-irradiating surveillance such as MRI and ultrasound [24]. Of the 10 female TP53
mutation carriers with breast cancer we have estrogen receptor (ER) and Herceptin receptor
(HER) status of 6 cancers. Four of six breast cancers were ER+ and HER+ whereas one was ER
+, HER-, and one was ER-, HER+. This underscores previous reports that receptor status in
early onset breast cancer should not necessarily dissuade panel testing [2,25].
Knowledge of TP53 mutation carrier status has other implications for health management.
As TP53 mutations causes DNA instability it has been theorized that germline mutations in
this gene increases risk of radiation-induced cancers. This theory is supported by observations
in a cohort study where secondary cancers were observed at or near the site of radiation [2].
Furthermore, reproduction possibilities with either preimplantation diagnostics or prenatal
diagnosis play an increasing role in fertile TP53 mutation carriers [26]. Interestingly, knowl-
edge of an underlying germline TP53 mutation may also help guide diagnosis, as demonstrated
in subject II.1 in family #9, who was shown to have a de novo R248W missense mutation. The
child presented with a brain tumor of uncertain histological type and unknown origin, and the
identification of a germline TP53 mutation supported the diagnosis of a choroid plexus
carcinoma.
While this study highlights the severe phenotype of LFS, we also observed a male mutation
carrier (II.4, family #10) who, at the time of this study, had reached 81 years of age without
developing cancer. Among his four daughters who have inherited the mutation, two developed
cancer at 31 and 37 respectively, while two are 51 and 56 and unaffected. Collectively the fam-
ily has 7 documented carriers, without a single occurrence of childhood cancer.
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Our study had several shortcomings, including an ascertainment bias due to the incorpo-
ration of the breast cancer gene panel screening in the clinical setting. Furthermore, a few his-
torical cases of LFS in Denmark may have been overlooked, however, these are likely to be
small and without recent instances of cancer.
In conclusion, this detailed nation-wide curation of known LFS families identified 5 novel
germline mutations, and emphasized the likelihood that such families are critically underdiag-
nosed. This report highlights the importance of raising awareness of LFS among health-care
professionals to ensure that patients and physicians can make informed decisions about treat-
ment, follow-up and reproduction. Following the recent advances in surveillance possibilities
of LFS patients, the use of only strict clinical criteria and lack of pre-symptomatic testing may
lead to the mismanagement of some individuals or families. Studies offering population-based
genetic screening to patients with tumors within the LFS spectrum are needed, to further eluci-
date the prevalence and diagnostic yield as compared to the current approach based largely on
strict clinical criteria.
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gene (p.(Pro151Ser), p.(Arg175His), p.(Ile195Thr), p.(Tyr205Cys), p.(Arg248Trp), p.
(Arg267Trp), p.(Arg273His), p.(Arg282Gln)) vs. 6 mutations that are either outside of the
DNA-binding domain or non-missense mutations (c.672+2T>G, p.?, c.993G>A, p.?, c.80del,
p.(Pro27Leufs17), c.528C>A, p.(Cys176), c.919+1G>A, p.?, c.994_1139del, p.(Ile332)).
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